Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.44 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.35 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.34 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.34 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.34 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.34 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31532309 | 0.98 | CD44 (0.44) | ALDH1A1GAAMAPTCD44KDM4E | |
| SCHEMBL2527588 | 0.98 | CD44 (0.44) | ALDH1A1GAAMAPTCD44KDM4E | |
| Hydrochloric Acid SCHEMBL8223051 | 0.88 | ACHE (0.43) | ALDH1A1GAAMAPTCD44KDM4E | |
| SCHEMBL6065571 | 0.80 | HSD17B10 (0.46) | ALDH1A1GAAMAPTCD44KDM4E | |
| SCHEMBL17744621 | 0.77 | CD44 (0.41) | ALDH1A1GAAMAPTCD44KDM4E | |
| SCHEMBL11155205 | 0.77 | HSD17B10 (0.59) | ALDH1A1GAAMAPTCD44KDM4E | |
| SCHEMBL10771021 | 0.77 | HSD17B10 (0.59) | ALDH1A1GAAMAPTKDM4ELMNA | |
| Hydrochloric Acid SCHEMBL30758778 | 0.76 | THRB (0.43) | ALDH1A1GAAMAPTKDM4ELMNA | |
| Hydrochloric Acid SCHEMBL8088986 | 0.75 | GABRA1 (0.38) | ALDH1A1GAAMAPTCD44KDM4E | |
| SCHEMBL7023508 | 0.75 | HSD17B10 (0.44) | ALDH1A1GAAMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-7550510-B2 | Solid phase synthesis of arylretinamides | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1985297-A1 | CARBOXYLIC ACID COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | JAPAN TOBACCO INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | disclosed |
| CN-1701061-A | Novel compounds for inhibiting rotamase enzymes and uses thereof | JERINI AG (DE) | 2005-11-23 | — | — | CN | disclosed |
| EP-1539683-A2 | PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS | Jerini AG (DE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040102650-A1 | Solid phase synthesis of arylretinamides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-05-27 | — | — | US | disclosed |
| WO-2004030664-A2 | NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF | JERINI AG (DE) | 2004-04-15 | — | — | WO | disclosed |
| WO-1998022822-A1 | PHOTOGRAPHIC COLOR COUPLERS USED AS CYTOCHEMICAL CONTRAST MARKERS | APPLIED IMAGING CORPORATION (US) | 1998-05-28 | — | — | WO | disclosed |
| US-5442114-A | Process for producing aromatic amide compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-08-15 | — | — | US | disclosed |
| US-5382502-A | Photography, simplified synthesis | EASTMAN KODAK COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0608896-A1 | Process for producing aromatic amide compounds useful as cyan coupler for color photographes | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-08-03 | — | — | EP | disclosed |
| US-5260257-A | Use of a sublimation dye, provides clear image, sufficcent density, color/light fastness, and migration resistance | DAI NIPPON PRINTING CO., LTD. (JP) | 1993-11-09 | — | — | US | disclosed |
| US-5128312-A | Thermal transfer dye donating material | FUJI PHOTO FILM CO., LTD. (JP) | 1992-07-07 | — | — | US | disclosed |
| US-4495272-A | CYAN COLOR IMAGE FORMING POLYMER COUPLER LATEX | FUJI PHOTO FILM CO., LTD. (JP) | 1985-01-22 | — | — | US | disclosed |
| US-4455366-A | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
| US-4241172-A | COLORFAST COUPLERS | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1980-12-23 | — | — | US | disclosed |
| US-4110116-A | Fogged direct positive silver halide emulsion containing a cyanine dye having at least one benzoxazole or benzothiazole nucleus substituted with halogen atoms | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | GAA 4010/4885CA2 2053/4885CHRM1 20/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | GAA 3384/4885CA2 1651/4885CHRM1 23/4885 |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | GLS, SLC10A1, SOAT1 | GAA 783/4885CA2 363/4885CHRM1 3676/4885 |
| US-20040102650-A1 | Solid phase synthesis of arylretinamides | RARA, LRAT, NR2E3 | GAA 3855/4885CA2 2791/4885CHRM1 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.